In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Parkinson's disease (PD) is characterized by abnormal alpha-synuclein (α-syn) aggregation, forming Lewy bodies.
• The mTOR pathway and glutamatergic signaling are implicated in protein aggregation processes.

Purpose of the Study:

• To investigate the effects of the mTOR inhibitor rapamycin and the mGluR5 modulator CTEP on α-syn aggregation in a cellular model of PD.
• To explore the potential of these compounds in promoting the clearance of pathological α-syn.

Main Methods:

• Utilized preformed α-syn fibrils and an A53T mutant α-syn adenovirus to induce aggregation in SH-SY5Y neural cells.
• Administered rapamycin and CTEP to assess their impact on α-syn fibril levels.
• Monitored mTOR signaling and autophagic pathway markers.

Main Results:

• Both rapamycin and CTEP significantly reduced α-syn fibril accumulation in SH-SY5Y cells.
• Treatment with these compounds led to decreased mTOR signaling.
• Enhanced autophagic pathway factors were observed following treatment.

Conclusions:

• Rapamycin and CTEP demonstrate potential as therapeutic agents for Parkinson's disease.
• These compounds may exert their effects by promoting intracellular degradation and clearance of aggregated α-syn.